ACE Inhibitor and ARB Utilization and Expenditures in the Medicaid Fee-For-Service Program from 1991 to 2008

Boyang Bian, MS; Christina M.L. Kelton, PhD; Jeff J. Guo, PhD; and Patricia R. Wigle, PharmD

ABSTRACT

BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are widely prescribed for the treatment of hypertension and heart failure, as well as for kidney disease prevention in patients with diabetes mellitus and the management of patients after myocardial infarction.

OBJECTIVE: To (a) describe ACE inhibitor and ARB utilization and spending in the Medicaid fee-for-service program from 1991 through 2008, and (b) estimate the potential cost savings for the collective Medicaid programs from a higher ratio of generic ACE inhibitor utilization.

METHODS: A retrospective, descriptive analysis was performed using the National Summary Files from the Medicaid State Drug Utilization Data, which are composed of pharmacy claims that are subject to federally mandated rebates from pharmaceutical manufacturers. For the years 1991-2008, quarterly claim counts and expenditures were calculated by summing data for individual ACE inhibitors and ARBs. Quarterly per-claim expenditure as a proxy for drug price was computed for all brand and generic drugs. Market shares were calculated based on the number of pharmacy claims and Medicaid expenditures.

RESULTS: In the Medicaid fee-for-service program, ACE inhibitors accounted for 100% of the claims in the combined market for ACE inhibitors and ARBs in 1991, 80.6% in 2000, and 64.7% in 2008. The Medicaid expenditure per ACE inhibitor claim dropped from $37.24 in 1991 to $24.03 in 2008 when generics accounted for 92.5% of ACE inhibitor claims; after adjusting for inflation for the period from 1991 to 2008, the real price drop was 59.2%. Brand ACE inhibitors accounted for only 7.5% of the claims in 2008 for all ACE inhibitors but 32.1% of spending; excluding the effects of manufacturer rebates, Medicaid spending would have been reduced by $28.7 million (9%) in 2008 if all ACE inhibitor claims were generic. The average price per ACE inhibitor claim in 2008 was $24.03 ($17.64 per generic claim vs. $103.45 per brand claim) versus $81.98 per ARB claim. If the ACE inhibitor ratio had been 90% in 2008, the cost savings for the combined Medicaid fee-for-service programs would have been about 33% or about $102.3 million. The total cost savings opportunity with 100% generic ACE inhibitor utilization in 2008 and an ACE inhibitor ratio of 75% was $75.1 million (24%) or $142.3M (46%) with a 90% ACE inhibitor ratio.

CONCLUSION: Factors that affect Medicaid spending by contributing to increased utilization of ACE inhibitors and ARBs, such as the rising prevalence of hypertension, heart disease, and diabetes, can be offset by reduction in the average price attained through a higher proportion of ACE inhibitors and a higher percentage of generic versus brand ACE inhibitors.

J Manag Care Pharm. 2010;16(9):671-79

What is already known about this subject

• Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) are both widely used in the treatment of hypertension and heart failure and in the prevention of macrovascular and microvascular cardiovascular outcomes associated with hypertension and diabetes. In 2009, ACE inhibitors were the fourth most utilized drug class in the United States with 162.8 million prescriptions, and ARBs were the eleventh most utilized drug class with 82.5 million prescriptions.

• Utilization of ACE inhibitors and ARBs may be cost-effective for their approved indications particularly when generic drugs are used in place of brand name drugs. Captopril was the first generic ACE inhibitor at year-end 1995, but it was almost 5 years before the class became relatively inexpensive with the introduction of generic enalapril in 2000 Q3 and lisinopril in 2002 Q3. The first generic ARB (losartan and losartan/HCTZ) entered the U.S. market in April 2010.

What this study adds

• In 2008, state Medicaid fee-for-service programs spent approximately $310 million for both ACE inhibitors ($108 million) and ARBs ($202 million). ARBs represented only 35.3% of the total claims but 65.1% of the total combined expenditure because of the higher average price per claim, $81.98 for ARBs versus $24.03 for ACE inhibitors.

• With generic drug entry for the ACE inhibitors, the average price per ACE inhibitor claim declined from approximately $37 in 1991 to $24 in 2008, while the average price for ARB claims increased from approximately $38 in 1995 to $82 in 2008.

• If the 7.5% of all ACE inhibitor claims that were brand in 2008 were substituted with generic ACE inhibitors, the average price per claim would have been $17.64 rather than $24.03, representing a savings opportunity of $28.7 million (9%) for the Medicaid fee-for-service programs for combined ACE inhibitor-ARB spending. The total cost savings opportunity was as much as $142.3 million (46%), attainable with 100% generic ACE inhibitors and a 90% ratio of ACE inhibitors to total ARB and ACE inhibitors, associated with a reduction in the average price per claim from $44.52 to $24.07, excluding the effects of manufacturer rebate payments.
Hypertension is a major risk factor for the development of cardiovascular disease, including coronary artery disease, stroke, and heart failure. According to the American Heart Association, there were 74.5 million people with hypertension (representing a 33.6% adult prevalence rate) and 5.8 million with heart failure in the United States (a 2.6% adult prevalence rate) in 2006. In 2007, an estimated 17.5 million people in the United States were diagnosed with type 1 or type 2 diabetes, a disease that often coexists with hypertension.

Although thiazide-type diuretics are recommended as first-line therapy for uncomplicated hypertension, patients with stage 2 hypertension (systolic blood pressure equal to or greater than 160 mmHg) should be treated with a combination of 2 antihypertensive medications. Angiotensin-converting enzyme (ACE) inhibitors are widely used in the treatment of hypertension. Their effect on the renin-angiotensin-aldosterone system, combined with improved ventricular remodeling, make ACE inhibitors an attractive option for heart failure patients, as well as for patients who have had a myocardial infarction. Multiple effects on the kidney, including a decrease in renovascular resistance, make ACE inhibitors appropriate also for decreasing the progression of nephropathy in patients with diabetes. Labeled indications besides hypertension for the various ACE inhibitors include congestive heart failure; to improve survival following myocardial infarction; stable coronary artery disease; risk reduction for myocardial infarction, stroke, and death from cardiovascular causes; and left ventricular dysfunction after myocardial infarction.

The first ACE inhibitor, captopril (Capoten), was approved by the U.S. Food and Drug Administration (FDA) in 1981 to treat hypertension and enjoyed market exclusivity for almost 5 years until the second ACE inhibitor, enalapril (Vasotec), was introduced at the end of 1985. Following enalapril, a number of other brand ACE inhibitors entered the market (Table 1). The latest FDA-approved ACE inhibitor was trandolapril (Mavik) in 1996. Many of the ACE inhibitors are also marketed as combination drugs either with a diuretic (e.g., Lotensin-HCT; benazepril and hydrochlorothiazide [HCTZ]) or with a calcium channel blocker (e.g., Lotrel; benazepril and amlodipine). All of the ACE inhibitors now have generic equivalents in 2010. According to IMS Health, of 3.9 billion prescriptions dispensed in the United States in 2009, 162.8 million (4.2%) were for ACE inhibitors. Only 3 drug classes had more prescriptions dispensed in 2009: lipid regulators, codeine and combinations, and antidepressants.

Angiotensin receptor blockers (ARBs), a newer class of antihypertensives, are also widely prescribed either as monotherapy or in combination with a diuretic or calcium channel blocker. Along with hypertension, labeled indications for the ARBs include heart failure, nephropathy in type-2 diabetic patients, left ventricular hypertrophy, reduction in the risk of stroke, and reduction in cardiovascular mortality following a myocardial infarction. ARBs are also prescribed for patients who cannot tolerate an ACE inhibitor-induced cough. On April 14, 1995, the FDA approved the first ARB, losartan (Cozaar), for clinical use in the United States. Cozaar dominated the ARB market briefly (Table 1). The most recent FDA approval of an ARB was olmesartan (Benicar) in April 2002. Although none of the ARBs experienced generic entry during the study period, generic losartan and losartan/HCTZ have been available in the U.S. market since April 2010.

ARBs have not been shown to be more effective than ACE inhibitors in blood-pressure reduction or in slowing the progression of renal disease or slowing the progression to type-2 diabetes. ARBs are associated with a lower incidence of cough, but the absolute rates of cough are often low including the head-to-head trial of ramipril (4.2%) versus telmisartan (1.1%) in ONTARGET (Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial). In 2009, 82.5 million prescriptions were dispensed for ARBs (which represent approximately 2% of all U.S. prescriptions), and the ARB class was ranked eleventh in prescription volume. Cardiovascular mortality has been decreased by certain antihypertensive medications, including ACE inhibitors and ARBs.

Due to its high and rising prevalence, hypertension is an expensive disease. Moreover, the growing acceptance of ACE inhibitors and ARBs as first-line therapies in the treatment of hypertension coupled with a decline in cardiovascular disease mortality (leading to longer use of the antihypertensive medications) imply higher expenditures for drug treatment. A number of chronic disease conditions have propelled spending on prescription drugs, and Medicaid and Medicare combined spending on outpatient prescription drugs was over $70 billion in 2008, much higher than 2 decades ago (Figure 1). Although an abrupt drop in Medicaid expenditures accompanied the transfer of dual Medicaid-Medicare eligibles to Medicare Part D in 2006, an upward trend in Medicaid spending was seen between 2006 and 2008.

In response to rising prescription drug expenditures, state Medicaid programs have developed a variety of cost-containment strategies, including beneficiary cost sharing, preferred drug lists, formularies, requiring generic substitution, and prior authorization (PA) for certain types of medication. These strategies are not standardized, and each state has its own set of policies. Fischer and Avorn (2003) estimated that there were potential cost savings for Medicaid of $450 million from greater overall use of generic drugs. Due to the therapeutic interchangeability of ACE inhibitors and ARBs, coupled with the availability of inexpensive generic ACE inhibitors, many private payers require PA or step-therapy for ARBs. Hence, the present study has 2 objectives: (a) describe ACE inhibitor
and ARB utilization and spending in the Medicaid fee-for-service program from 1991 through 2008, and (b) estimate the potential cost savings for the Medicaid programs from a higher ratio of generic ACE inhibitor utilization.

## Methods

A retrospective, descriptive analysis was performed for the years 1991-2008 using the publicly available National Summary Files from the Medicaid State Drug Utilization Data maintained by the Centers for Medicare & Medicaid Services. The database covers Medicaid beneficiaries in 49 states (all except Arizona) and the District of Columbia and is restricted to outpatient pharmaceuticals. The National Summary Files in the present study were compiled by aggregating state databases; the method is described in detail below. Since the data are collected as part of the Medicaid Rebate Program, they include fee-for-service but not managed Medicaid pharmacy claims. States differ in how their drug benefit programs are managed. Arizona, for example, is not included in the database because it is 100% managed care (i.e., Arizona Medicaid pharmacy claims are not eligible for federally negotiated manufacturer rebates). The database appeared to contain coding errors in 2006 (all quarters) and 2007 Q3. During those 5 quarters, for some individual drugs including ACE inhibitors and ARBs, expenditures were incorrectly reported; hence, using the utilization data, which seemed to be correctly reported, we re-estimated expenditures for these 5 calendar quarters. For example, taking an average of per-unit (e.g., individual capsule or tablet) expenditure (i.e., pharmacy reimbursement) for quarters before and after the quarter in which a coding error occurred, we multiplied that average by the number of units. In this way, we came up with pharmacy reimbursement estimates that had better face validity. The general results from the present study were not affected by this small amount of data cleaning.

Each data record included the National Drug Code (NDC) number, drug name (trade or generic), year and quarter of Medicaid expenditure, number of pharmacy claims, number of units (e.g., individual capsules or tablets), and total pharmacy reimbursement amount, including drug cost and dispensing fee. The first 5 digits of the NDC number identified the drug manufacturer, while the remaining digits identify specific drug product by strength, dose formulation, and packaging. We searched the database for all ACE inhibitors and ARBs using both trade name and generic name (Table 1). For each of the drugs in Table 1, and for the ACE inhibitor and ARB classes overall, quarterly claim counts and reimbursement amounts were calculated by summing data across individual NDCs for each of the drugs and then for each class of drugs, respectively. Data for all the generic versions of each drug were aggregated, and all the combination drugs (with diuretic or calcium channel blocker) were aggregated with their stand-alone counter-parts (e.g., claims for lisinopril/HCTZ were combined with those for lisinopril). Market shares were calculated based on both number of prescriptions and Medicaid payments.
Quarterly per-claim pharmacy reimbursement, as a proxy for drug price, was computed for all brand and generic ACE inhibitors and ARBs. Pharmacy reimbursements include the drug ingredient cost and dispensing fee but do not include manufacturer rebates (i.e., federally mandated rebates and supplemental state rebates have not been subtracted). All the data analyses were conducted using the SAS software package for Windows (Version 9.1.3, SAS Institute Inc., Cary, NC). Excel 2007 (Microsoft, Redmond, WA) was used to further develop the data.

### Results

Table 2 shows prescription market shares for both the ACE inhibitor and ARB classes of drugs. Whereas ACE inhibitors had 100% of the Medicaid market in the number of claims from 1991-1994, their share fell to 64.7% by 2008. The share of brand drug prescriptions exceeded the share of generic prescriptions for ACE inhibitors through 2002. In 2003, this relationship reversed, and in 2008, 92.5% of Medicaid fee-for-service claims for ACE inhibitors were generic. All of the ARBs were still under patent and without generic competition at the end of the study period in 2008. Table 2 also shows payment market shares for the ACE inhibitors and ARBs. For the first time in 2007, and continuing in 2008, Medicaid spending on generic ACE inhibitors exceeded its spending on brand drugs in this class. Although brand drugs represented only 7.5% of the ACE inhibitor claims in 2008, they accounted for 32.1% of expenditures because their average price ($103.45) was almost 6 times the average generic ACE inhibitor price ($17.64; Table 3).

By 2005, the dollar market share for ARBs was higher than for ACE inhibitors and remained higher through 2008. In 2005, the ARBs accounted for 51.5% of Medicaid expenditures in the 2 drug classes rising to 65.1% in 2008. The last 3 columns of Table 2 show the annual pharmacy payments (prices) per claim for the ACE inhibitors, ARBs, and for both drug classes combined. In 1991, an average pharmacy claim for an ACE inhibitor cost these Medicaid programs $37.24. In 2008, the average price per claim had fallen to $24.03. After adjusting both values by their year-appropriate consumer price index (CPI) values (136.2 and 215.3 base 1982-1984 for 1991 and 2008, respectively, for an inflation rate of 58.1%), Medicaid enjoyed a real price drop of 59.2% for ACE inhibitors in 2008 compared with 1991. In contrast, the average price of an ARB prescription rose from $38.24 in 1995 to $81.98 in 2008. After adjusting by the change in the CPI (from 152.4 in 1995 to 215.3 in 2008, for an inflation rate of 41.3%), the average ARB price rose in real terms by 51.7% from 1995 to 2008. Figure 2 shows the trends in average ACE inhibitor and average ARB prices along with the trend in the CPI over the same time period from 1991 to 2008.

In 2008, the Medicaid programs combined spent $309.8 million on ACE inhibitors and ARBs, with 64.7% of the claims for ACE inhibitors. At an average price per claim of $24.03, ACE inhibitors were significantly cheaper than the ARBs, which cost an average of $81.98 per claim. If the ACE inhibitor share had been reduced from 35.3% to 25.0%, an attainable goal, the average price per claim would have fallen from
would have produced cost savings of $142.3 million (46%),

$44.52 to $38.52, and Medicaid program expenditures would have been $41.8 million less in 2008. The savings opportunity was $102.3 million in 2008 if the ACE inhibitor ratio had been 90%, with a reduction in the average price per claim from $44.52 to $29.83.

On top of these savings, there are some additional savings from a higher percentage of generic, versus brand, ACE inhibitor prescriptions. In 2008, there were 335,925 claims for brand ACE inhibitors at an average price of $103.45 per claim, compared with the $17.64 average for generic ACE inhibitor claims (Table 3). Multiplying the number of claims by the difference in price of $85.81 per claim means that there was an additional unrealized savings opportunity of $28.7 million if all ACE inhibitors were dispensed as generic in 2008.

The maximum savings opportunity in 2008, attainable through greater use of generic ACE inhibitors, was $75.1 million if all ACE inhibitors were dispensed as generic and 75% of the combined ACE inhibitors and ARBs were dispensed as ACE inhibitors; the average price per claim would have been $33.73 instead of $44.52. Even higher utilization of generic ACE inhibitors at 90% of the combined ACE inhibitors and ARBs would have produced cost savings of $142.3 million (46%), associated with a reduction in the average price per claim from $44.52 to $24.07.

By dividing total reimbursement by the number of claims,
Discussion

The $309.8 million in total Medicaid fee-for-service expenditures on ACE inhibitors and ARBs combined represented approximately 1.5% of total Medicaid spending of approximately $21.0 billion on outpatient prescription drugs (Figure 1). From 1991 to 2005, the year before the Medicaid-Medicare dual eligibles were moved to Medicare Part D, Medicaid’s spending on ACE inhibitors and ARBs rose from $179.2 million to over $1 billion (Table 2). There are several reasons for the 458% increase in spending on ACE inhibitors and ARBs. First, Medicaid enrollment has been increasing over time; in 1991, there were 28.3 million Medicaid beneficiaries, and by 2005, there were 45.4 million Medicaid beneficiaries, a 60% increase in enrollment over this 14-year period. In 2006, dual Medicaid-Medicare eligibles were transferred to Medicare Part D for their pharmacy benefit, resulting in a large drop in Medicaid spending for pharmaceuticals. However, the current economic recession that started in December 2007 brought significant job losses, loss of employer-offered health insurance, and a rise in the number of households requiring public assistance. Second, the prevalence of cardiovascular disease and diabetes has been rising in the United States. The age-adjusted hypertension prevalence over the period 1988 to 1994 was 24.4% among U.S. adults, rising to 28.9% during the average per-claim prices can be determined for all of the individual ACE inhibitors and ARBs. All of the brand ACE inhibitors and ARBs have had rising prices over time. For example, the price of brand captopril (Capoten) rose from $40.94 in 1991 Q1 to $230.39 in 2008 Q4, representing a 462.8% increase, far exceeding the rate of inflation over this period. The price of brand enalapril (Vasotec) rose from $35.09 in 1991 Q1 to $118.36 in 2008 Q4. The price of brand benazepril went up from $84.60 in 2004 Q2 to $120.63 in 2008 Q4, representing a 42.6% increase in just 4.5 years. The price of brand valsartan (Diovan) rose by 97% from $44.38 in 1997 Q1 to $87.52 in 2008 Q4.

The average prices of generic captopril, enalapril, and lisinopril showed a steady decline after the entry of additional generic manufacturers. By 2008 Q4, the average price per claim was $9.93, $29.62, and $10.30 for captopril, enalapril, and lisinopril, respectively. The price of captopril decreased 85% from $55.30 in 1996 Q3 to $8.28 in 2005 Q4 as more and more captopril manufacturers entered the market and as the Medicaid programs were able to capture these savings through their reimbursement policies. Table 3 shows average prices for brand and generics for each of the ACE inhibitors and ARBs in 2008. Average reimbursement per claim was higher for several of the brand ACE inhibitors than for the ARBs, but the volumes were, of course, smaller (data not shown).
period from 1999 to 2004. The age-adjusted (child plus adult) diabetes prevalence nearly doubled from 3.0% in 1991 to 5.7% in 2007. Third, the mortality rate for cardiovascular disease has decreased over time; hence, individuals are now taking ACE inhibitors and ARBs, chronic heart medications, for longer periods. Since 1968, cardiovascular disease death rates have fallen in the United States, including a 4.0% average annual decline in the age-adjusted mortality rate from cardiovascular diseases from 1999 to 2006. Finally, clinical guidelines and clinical trial results have encouraged increased prescribing of ACE inhibitors and ARBs.

Therefore, the increase in Medicaid spending on ACE inhibitors and ARBs is primarily attributable to increased utilization and not to price increases, although brand prices rose throughout the period. As shown in the last column of Table 2, the average price per claim rose from $37.24 in 1991 to $41.02 in 2005, representing just a 10% increase.

The rise in utilization of these drugs is probably not due to combination therapy with ARBs and ACE inhibitors because combination therapy with these 2 drugs is not encouraged in the United States. The Val-HeFT (Valsartan Heart Failure Trial) study showed beneficial effects on the combined endpoint of morbidity and mortality in patients who received an ARB in addition to ACE-inhibitor therapy, but subgroup analysis showed deleterious effects on morbidity and mortality when an ARB was given to patients receiving background therapy consisting of an ACE inhibitor plus a beta-blocker. Moreover, the ONTARGET study suggested that although the combination therapy can cause further reduction of albuminuria relative to ACE inhibitor or ARB monotherapy, the combination therapy had an adverse effect on renal function. In summarizing the results of the 4 trials devoted to ACE inhibitor and ARB combination therapy, McMurray (2008) concluded that the addition of an ARB to an ACE inhibitor had no benefit and increased the number of adverse events in patients with arterial disease. For patients with heart failure, however, the addition of an ARB might be beneficial. Generally, in the United States, hypertensive patients take either an ACE inhibitor or ARB but not both.

The influences on spending already discussed are largely beyond the control of state Medicaid programs. However, there are 2 Medicaid policies that can have a major impact on spending in these drug classes. First, most state Medicaid programs either require or strongly encourage the use of generic drugs when they become available following patent expiration of their brand counterparts. In 2008, 93.5% of Medicaid fee-for-service ACE inhibitor pharmacy claims were for generics. However, since the average price per brand ACE inhibitor claim was $103.45 compared with an average generic price per claim of $76.64, the Medicaid state programs together could have saved $28.7 million (for 335,925 brand ACE inhibitor claims) if they had reimbursed for generic claims only in 2008. Second, greater use of ACE inhibitors relative to ARBs would have produced large savings, but this cost outcome would have required interventions such as PA or step-therapy for the ARBs.

Since ACE inhibitors are well tolerated, the step-up approach from ACE inhibitors to ARBs is promising for reducing Medicaid spending. According to our analysis, Medicaid fee-for-service programs could have saved between $41.8 million and $102.3 million with PA for ARBs in 2008, depending on the assumptions made about the ratio of utilization of ARBs.

Research reported in this journal by Yokoyama et al. found significant cost savings associated with step-therapy for ARBs implemented in May 2001 in 3 health plans with approximately 1 million members. The proportion of ACE inhibitor or ARB patients who received an ARB was reduced from 31% to 18% in the 12 months following the intervention, producing $368,000 in annual savings or $0.03 per member per month (PMPM). An accompanying editorial pointed out that the cost savings were actually $0.06 PMPM if the step-therapy intervention had been followed for a full year, closer to the cost savings of $0.11 PMPM reported by Gleason et al. for an ARB step-therapy intervention that was implemented in 2006. Although some state Medicaid programs such as Massachusetts, Washington, Maine, and Indiana have a PA requirement, not all do. Fischer et al. (2007), compared Medicaid expenditures for states with a PA requirement versus those without and found that step-therapy did indeed reduce ARB use and provided a method to significantly reduce Medicaid spending on antihypertensives.

### Limitations

First among the limitations is the potential invalidity of the Medicaid national database. When we summed all Medicaid fee-for-service claims in 2008 in the national database, we found that Medicaid had a total of $24.3 billion in expenditures on all outpatient prescription drugs. This number compares with the $21.0 billion National Health Expenditure figure upon which Figure 1 is based, but the $21 billion figure apparently includes spending on Medicaid beneficiaries in managed care as well as fee-for-service. Some of the higher cost in the national database of fee-for-service claims is explained by pharmacy reimbursement prior to subtraction of drug manufacturer rebates. However, the proportion of total Medicaid beneficiaries has risen significantly, from only 9.5% in 1991 to 40.1% in 1996 and 70.9% in 2008. We did not determine the extent to which the national Medicaid fee-for-service database that we used includes managed Medicaid pharmacy benefits that are carved out of managed care.

Second, we discovered apparent errors in the national fee-for-service database for 5 calendar quarters from the inception of Medicare Part D program in January 2006 through the first quarter of 2007, necessitating our recalculation of expenditures...
to match the claims volume for ARBs and ACE inhibitors. However, these data manipulations did not affect our primary cost savings calculations, which were based on claims data in 2008.

A third limitation of this research is the inability to consider the effects of drug manufacturer rebates in reducing the net cost to the Medicaid programs. The Medicaid Drug Rebate Program, established by the Omnibus Budget Reconciliation Act of 1990, requires a drug manufacturer to enter into and have in effect a national rebate agreement with the secretary of the Department of Health and Human Services in order for states to receive federal funding for outpatient drugs dispensed to Medicaid patients. Rebate percentages are based on average manufacturer prices, and the percentage is higher for innovator drugs than for noninnovator (generic) drugs. In addition, a number of states have been collecting state-only supplemental rebates in conjunction with a preferred drug list. Therefore, the claims data that we used in the present study overstate the actual net drug acquisition cost to the Medicaid programs by ignoring rebates and do not include the managed Medicaid pharmacy claims that are not part of the federally administered Medicaid Drug Rebate Program.

Conclusions

In 2008, state Medicaid programs spent $309.8 million on ACE inhibitors and ARBs. Although many factors explaining this expense by affecting utilization (e.g., prevalence of hypertension, heart disease, and diabetes) are beyond the control of program administrators, cost savings can be obtained through a higher percentage of generic drug prescriptions and a higher percentage of ACE inhibitors in the total of ACE inhibitor and ARB utilization. In 2008, Medicaid could have saved up to $28.7 million (9%) through 100% utilization of generic ACE inhibitors and up to $142.3 million from 90% utilization of ACE inhibitors in the combined class of ARBs and ACE inhibitors.

Disclosures

Guo reported consulting relationships with pharmaceutical manufacturers with brand drugs in the class of ACE inhibitors and ARBs, including Novartis, AstraZeneca, and Bristol-Myers Squibb. The other 3 authors reported no financial or other potential conflicts of interest related to the subject of this manuscript. A preliminary version of this study was presented as an unpublished poster at the 15th Annual Meeting of the International Society for Pharmacoeconomics and Outcomes Research in Atlanta, Georgia, in May 2010.

All 4 authors contributed to the study concept and design. Bian collected the data with the assistance of Guo. Bian and Kelton interpreted the data and wrote and revised the manuscript with the assistance of Guo and Wigle.

Acknowledgments

The authors appreciate the comments and suggestions of the editors and 3 anonymous reviewers of this manuscript.

References


